Psychedelic Medicine

Association

Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice

Excerpts from the publication

Psychedelics have been already used by human societies for more than 3000 years, mostly in religious and healing context. The renewed interest in the potential application of psychedelic compounds as novel therapeutics has led to promising preliminary evidence of clinical benefit in some psychiatric disorders. Despite these promising results, the potential for large-scale clinical application of these profoundly consciousness-altering substances, in isolation from the sociocultural contexts in which they were traditionally used, raises important concerns. These concerns stem from the recognition that the mechanisms of therapeutic action of psychedelics are not entirely dependent on neurobiology, but also on the psychological, social and spiritual processes for their efficacy. For these reasons, physicians or psychotherapists involved in psychedelic-assisted psychotherapy need training in ways to accompany patients through this experience to promote positive outcomes and address potential side effects. Psychedelic therapies may foster the emergence of a novel paradigm in psychiatry that integrates psychopharmacological, psychotherapeutic, and cultural interventions for patients with mental health issues.

Read more

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials

Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: A case report

Modern Psychedelic Microdosing Research on Mental Health: A Systematic Review

Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study